Cellectar shares fall 10.87% intraday on expected $2.02/share loss.

Cellectar Biosciences Inc. fell 10.87% intraday trading as the stock reacted to reports that the company is expected to post a loss of $2.02 per share. The earnings forecast, which aligns with the firm’s ongoing challenges in its drug development pipeline and operational costs, likely triggered selling pressure among investors anticipating weak financial results. The decline reflects market skepticism toward Cellectar’s ability to offset losses through near-term revenue growth or strategic advancements, compounding concerns about its long-term viability in the biopharmaceutical sector.